Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
| Technology Name (St. Jude Reference #) |
Anaplastic Lymphoma Kinase (ALK) (SJ-93-0002) |
| Description | ALK is a kinase associated with several different types of cancer and can be used as a drug screening target. ALK inhibitors are contemplated to be useful as anti-cancer therapeutics. ALK antibodies are also provided. |
| Related Reagents | ALK antibody |
| Keywords | ALK, kinase, lymphoma, cancer, vaccine |
| Granted Patents or Published Applications | U.S. Patent Nos. 5,529,925; 5,770,421; 6,174,674; 6,451,997; 6,696,548; Australian Patent No. 679,833; European Patent No. 731,806 |
| Related Scientific References | Morris, S.W. et al., “Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in Non-Hodgkin’s Lymphoma”, Science 263: 1281-1284 (1994); Li, R and Morris, SW, "Development of Anaplastic Lymphoma Kinase (ALK) small molecule inhibitors for cancer therapy", Medicinal Research Reviews 28(3):372-412 (2008). |
| Licensing Opportunities | We are currently seeking nonexclusive licensing opportunities in all fields for the development of this technology. Certain aspects of this technology are co-owned. |
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: September 2008
